70 phenotypes from 9 alleles in 11 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Hrastm1Esn/Hrastm1Esn involves: 129X1/SvJ * C57BL/6N	no abnormal phenotype detected	J:67374
Hrastm1Grnt/Hrastm1Grnt involves: 129P2/OlaHsd	normal nervous system phenotype	J:98903
Hrastm1Jaf/Hras+ Tg(CAG-cre)13Miya/0 involves: 129S6/SvEvTac * Black Swiss * C57BL/6	abnormal ameloblast differentiation	J:204891
	abnormal ameloblast morphology	J:148393, J:204891
	abnormal cervical loop morphology	J:204891
	abnormal enamel mineralization	J:148393, J:204891
	abnormal enamel morphology	J:204891
	abnormal enamel rod pattern	J:204891
	abnormal stellate reticulum morphology	J:204891
	abnormal stratum intermedium morphology	J:204891
	abnormal suckling behavior	J:148393
	abnormal tooth development	J:204891
	absent enamel	J:204891
	cardiac fibrosis	J:148393
	deviated nasal septum	J:148393
	domed cranium	J:148393
	increased hemangiosarcoma incidence	J:148393
	increased papilloma incidence	J:148393
	increased skin papilloma incidence	J:148393
	increased stomach tumor incidence	J:148393
	jaw cyst	J:204891
	malocclusion	J:148393
	postnatal growth retardation	J:148393
	postnatal lethality, incomplete penetrance	J:148393
	premature death	J:148393
Hrastm1Jaf/Hrastm1Jaf Tg(TPO-cre)1Shk/0 involves: 129S6/SvEvTac * FVB/NCr	normal neoplasm	J:231492
Hrastm1Jaf/? Tg(TPO-cre)1Shk/0 involves: 129S6/SvEvTac * FVB/NCr	normal endocrine/exocrine gland phenotype	J:168249
	normal neoplasm	J:168249
Hrastm1Mok/Hrastm1Mok involves: 129S/SvEv * C57BL/6 * DBA/2	chylous ascites	J:159024
	decreased incidence of tumors by chemical induction	J:62962
Hrastm1Rak/Hras+ B6.129S4-Hrastm1Rak	no abnormal phenotype detected	J:94077
Hrastm1Xbr/Hrastm1Xbr involves: 129S1/Sv * 129X1/SvJ * C57BL/6	no abnormal phenotype detected	J:137729
Hrastm2Xbr/Hrastm2Xbr involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N	abnormal aorta tunica media morphology	J:137729
	abnormal blood vessel morphology	J:137729
	abnormal branching of the mammary ductal tree	J:137729
	abnormal cranium morphology	J:137729
	abnormal facial morphology	J:137729
	abnormal frontal bone morphology	J:137729
	abnormal heart morphology	J:137729
	abnormal lip morphology	J:137729
	abnormal mammary gland development	J:137729
	abnormal vibrissa follicle morphology	J:137729
	normal cardiovascular system phenotype	J:137729
	choanal stenosis	J:137729
	decreased urine creatinine level	J:137729
	depressed nasal bridge	J:137729
	enlarged aortic valve	J:137729
	heart left ventricle hypertrophy	J:137729
	heart right ventricle hypertrophy	J:137729
	hypertension	J:137729
	increased circulating angiotensin II level	J:137729
	increased heart atrium size	J:137729
	increased heart ventricle size	J:137729
	increased mammary adenocarcinoma incidence	J:137729
	increased systemic arterial blood pressure	J:137729
	increased systemic arterial diastolic blood pressure	J:137729
	increased systemic arterial systolic blood pressure	J:137729
	mammary gland hyperplasia	J:137729
	normal neoplasm	J:137729
	renal fibrosis	J:137729
	normal renal/urinary system phenotype	J:137729
	normal respiratory system phenotype	J:137729
	short maxilla	J:137729
	short nasal bridge	J:137729
	short premaxilla	J:137729
	short zygomatic bone	J:137729
Tg(CAG-Bgeo,-Hras1,-EGFP)#Ichi/0 Tg(Flt4-cre)44Ichi/0 involves: 129P2/OlaHsd * C57BL/6J	lymphatic vessel hyperplasia	J:159024
Tg(CAG-Bgeo,-Hras1,-EGFP)#Ichi/0 Tg(Tek-cre)12Flv/0 involves: 129P2/OlaHsd * C3H * C57BL/6	normal cardiovascular system phenotype	J:159024
	edema	J:159024
	lethality throughout fetal growth and development, complete penetrance	J:159024
	lymphatic vessel hyperplasia	J:159024
Tg(GFAP-Hras1)2Agu/0 involves: 129S1/Sv * 129X1/SvJ * ICR	increased astrocytoma incidence	J:69129
	premature death	J:69129
Tg(GFAP-Hras1)2Agu/Tg(GFAP-Hras1)2Agu involves: 129S1/Sv * 129X1/SvJ * ICR	abnormal astrocyte morphology	J:69129
	ataxia	J:69129
	hydrocephaly	J:69129
	increased astrocytoma incidence	J:69129
	postnatal growth retardation	J:69129
	premature death	J:69129
	trisomy	J:69129